ICD-10 Coding for Myelofibrosis(D47.4, D47.4B, D47.4C)
Comprehensive guide on ICD-10 coding for myelofibrosis, including primary and secondary codes, documentation requirements, and common pitfalls.
Complete code families applicable to Myelofibrosis
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| D47.4 | Chronic myeloproliferative disease | Use for primary myelofibrosis with documented bone marrow findings and mutation status. |
|
| D75.81 | Other specified diseases of blood and blood-forming organs | Use for secondary myelofibrosis with documentation of the underlying condition. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutMyelofibrosis
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Myelofibrosis.
Omitting mutation status in documentation
Impact
Clinical: Inaccurate diagnosis and treatment planning., Regulatory: Non-compliance with coding standards., Financial: Potential for claim denials.
Mitigation
Ensure mutation testing is documented, Include mutation status in clinical notes
Coding anemia separately when it is integral to myelofibrosis
Impact
Reimbursement: Incorrect DRG assignment leading to lower reimbursement., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data representation.
Mitigation
Do not code D63.0 unless anemia requires separate treatment.
Principal diagnosis selection
Impact
Incorrect selection of principal diagnosis can lead to audit issues.
Mitigation
Verify documentation supports the principal diagnosis choice.